Cutaneous toxicities of antiretroviral therapy for HIV: Part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors

Journal of the American Academy of Dermatology

Volumn 63, Issue 4, 2010, Pages 549-561

  Introcaso, Camille E ^a   Hines, Janet M ^a   Kovarik, Carrie L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antiretroviral medications; cutaneous; drug eruption; HIV; toxicities

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALUVIA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RETROVIS; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SELZENTY; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ACNE; ALOPECIA; ALOPECIA AREATA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL TRIAL; CONTACT DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPERTRICHOSIS; LACTIC ACIDOSIS; LEUKOCYTOCLASTIC VASCULITIS; LIPODYSTROPHY; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS; XEROSTOMIA; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ERUPTIONS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; INCIDENCE; MALE; MEDICAL EDUCATION; PATHOPHYSIOLOGY; RISK ASSESSMENT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; EDUCATION, MEDICAL, CONTINUING; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INCIDENCE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT;

EID: 77956786331     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.01.061     Document Type: Review

References (121)

1. Joint United Nations Programme on HIV/AIDS. 2008 report on the global AIDS epidemic. http://data.unaids.org/pub/GlobalReport/2008/jc1510-2008-global- report-pp1-10-en.pdf ed. Geneva, Switzerland: UNAIDS and WHO; 2008.
2. A. Carr, and D.A. Cooper Adverse effects of antiretroviral therapy Lancet 356 2000 1423 1430
3. N. Kumarasamy, S. Vallabhaneni, A.J. Cecelia, T. Yepthomi, P. Balakrishnan, and S. Saghayam Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern india J Acquir Immune Defic Syndr 41 2006 53 58
4. N. Kumarasamy, K.K. Venkatesh, A.J. Cecelia, B. Devaleenal, A.R. Lai, and S. Saghayam Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients AIDS Patient Care STDS 22 2008 337 344
5. N. Phanuphak, T. Apornpong, S. Teeratakulpisarn, S. Chaithongwongwatthana, C. Taweepolcharoen, and S. Mangclaviraj Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women HIV Med 8 2007 357 366
6. T.R. Cressey, P. Leenasirimakul, G. Jourdain, M. Tod, P.O. Sukrakanchana, and S. Kunkeaw Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability J Antimicrob Chemother 55 2005 1041 1044
7. S.I. Pelton, K. Stanley, R. Yogev, C.V. Fletcher, K. McIntosh, and A. Wiznia Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children Clin Infect Dis 40 2005 1181 1187
8. A. Sharma, R. Vora, M. Modi, A. Sharma, and Y. Marfatia Adverse effects of antiretroviral treatment Indian J Dermatol Venereol Leprol 74 2008 234 237
9. I. Shah Adverse effects of antiretroviral therapy in HIV-1 infected children J Trop Pediatr 52 2006 244 248
10. T. Hawkins Appearance-related side effects of HIV-1 treatment AIDS Patient Care STDS 20 2006 6 18
11. L. Waters, and M. Nelson Long-term complications of antiretroviral therapy: lipoatrophy Int J Clin Pract 61 2007 999 1014
12. S. Grinspoon, and A. Carr Cardiovascular risk and body-fat abnormalities in HIV-infected adults N Engl J Med 352 2005 48 62 (Pubitemid 40075680)
13. J. Luther, and M.J. Glesby Dermatologic adverse effects of antiretroviral therapy: recognition and management Am J Clin Dermatol 8 2007 221 233
14. G. Chene, E. Angelini, L. Cotte, J.M. Lang, P. Morlat, and C. Rancinan Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients Clin Infect Dis 34 2002 649 657 (Pubitemid 34165328)
15. C. Hadigan, S. Borgonha, J. Rabe, V. Young, and S. Grinspoon Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy Metabolism 51 2002 1143 1147
16. D. Podzamczer, E. Ferrer, P. Sanchez, J.M. Gatell, M. Crespo, and C. Fisac Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study J Acquir Immune Defic Syndr 44 2007 139 147
17. Haubrich R, Riddler SA, DiRienzo AG, Komarow L, Powderly W, Garren KW, et al. Metabolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection, abstract #38. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
18. S. Peterson, C.R. Martins, and J. Cofrancesco Jr. Lipodystrophy in the patient with HIV: social, psychological, and treatment considerations Aesthet Surg J 28 2008 443 451
19. G.J. Moyle, L. Lysakova, S. Brown, N. Sibtain, J. Healy, and C. Priest A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection HIV Med 5 2004 82 87
20. S.L. Silvers, J.A. Eviatar, M.I. Echavez, and A.L. Pappas Prospective, open-label, 18-month trial of calcium hydroxylapatite (radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability Plast Reconstr Surg 118 3 suppl 2006 34S 45S
21. H.A. Ward, G.G. Russo, and J. Shrum Cutaneous manifestations of antiretroviral therapy J Am Acad Dermatol 46 2002 284 293
22. T. Saint-Marc, M. Partisani, I. Poizot-Martin, O. Rouviere, F. Bruno, and R. Avellaneda Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study AIDS 14 2000 37 49
23. G. Vaiopoulos, J. Mangakis, A. Karabinis, A. Kourtis, P. Fourtounis, and P. Fessas Nail pigmentation and azidothymidine Ann Intern Med 108 1988 777
24. A.P. Panwalker Nail pigmentation in the acquired immunodeficiency syndrome (AIDS) Ann Intern Med 107 1987 943 944
25. P.A. Furth, and A.M. Kazakis Nail pigmentation changes associated with azidothymidine (zidovudine) Ann Intern Med 107 1987 350
26. A. Azon-Masoliver, J. Mallolas, J. Gatell, and T. Castel Zidovudine-induced nail pigmentation Arch Dermatol 124 1988 1570 1571
27. C. Bendick, H. Rasokat, and G.K. Steigleder Azidothymidine-induced hyperpigmentation of skin and nails Arch Dermatol 125 1989 1285 1286
28. R.G. Greenberg, and T.G. Berger Nail and mucocutaneous hyperpigmentation with azidothymidine therapy J Am Acad Dermatol 22 2 pt 2 1990 327 330
29. C. Grover, S. Kubba, S. Bansal, S. Nanda, and B.S. Reddy Pigmentation: A potential cutaneous marker for AIDS? J Dermatol 31 2004 756 760
30. F. Granel, F. Truchetet, and M. Grandidier Diffuse pigmentation (nail, mouth and skin) associated with HIV infection Ann Dermatol Venereol 124 1997 460 462
31. G. Ficarra, C.M. Flaitz, D. Gaglioti, S. Piluso, D. Milo, and K. Adler-Storthz White lichenoid lesions of the buccal mucosa in patients with HIV infection Oral Surg Oral Med Oral Pathol 76 1993 460 466
32. S.M. Geletko, M. Segarra, and D.J. Mikolich Alopecia associated with zidovudine therapy Pharmacotherapy 16 1996 79 81
33. D.G. Diven, R.C. Newton, and K.M. Ramsey Heightened cutaneous reactions to mosquito bites in patients with acquired immunodeficiency syndrome receiving zidovudine Arch Intern Med 148 1988 2296
34. N.E. Klutman, and D.R. Hinthorn Excessive growth of eyelashes in a patient with AIDS being treated with zidovudine N Engl J Med 324 1991 1896
35. R.A. Torres, R.Y. Lin, M. Lee, and M.R. Barr Zidovudine-induced leukocytoclastic vasculitis Arch Intern Med 152 1992 850 851
36. H.H. Kong, and S.A. Myers Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients Dermatol Ther 18 2005 58 66
37. M. Wassef, and P. Keiser Hypersensitivity of zidovudine: report of a case of anaphylaxis and review of the literature Clin Infect Dis 20 1995 1387 1389
38. R. Murri, A. Antinori, G. Camilli, G. Zannoni, and G. Patriarca Fatal toxic epidermolysis induced by zidovudine Clin Infect Dis 23 1996 640 641
39. T.P. Cooley, L.M. Kunches, C.A. Saunders, C.J. Perkins, S.L. Kelley, and C. McLaren Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily Rev Infect Dis 12 suppl 5 1990 S552 S560
40. T.P. Cooley, L.M. Kunches, C.A. Saunders, J.K. Ritter, C.J. Perkins, and C. McLaren Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial N Engl J Med 322 1990 1340 1345 (Pubitemid 20154476)
41. C.L. Dodd, D. Greenspan, J.L. Westenhouse, and M.H. Katz Xerostomia associated with didanosine Lancet 340 1992 790
42. J.D. Allan, K.J. Connolly, H. Fitch, L. Jackson-Pope, C. McLaren, and R. Canetta Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine Clin Infect Dis 16 suppl 1 1993 S46 S51
43. P. Herranz, M.L. Fernandez-Diaz, R. de Lucas, J. Gonzalez-Garcia, and M. Casado Cutaneous vasculitis associated with didanosine Lancet 344 1994 680
44. A. Parneix-Spake, S. Bastuji-Garin, Y. Levy, M.L. Dubreuil-Lemaire, and J.C. Roujeau Didanosine as probable cause of Stevens-Johnson syndrome Lancet 340 1992 857 858
45. M. Just, J.M. Carrascosa, M. Ribera, I. Bielsa, and C. Ferrandiz Dideoxyinosine-associated Ofuji papuloerythroderma in an HIV-infected patient Dermatology 195 1997 410 411
46. Videx [package insert] 2007 Bristol-Meyers Squibb New York
47. P. Diz Dios, and C. Scully Adverse effects of antiretroviral therapy: focus on orofacial effects Expert Opin Drug Saf 1 2002 307 317
48. A. Vigano, P. Brambilla, L. Cafarelli, V. Giacomet, S. Borgonovo, and I. Zamproni Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz Antivir Ther 12 2007 297 302
49. G.A. McComsey, V. Lo Re 3rd, M. O'Riordan, U.A. Walker, D. Lebrecht, and E. Baron Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: A randomized, controlled study Clin Infect Dis 46 2008 1290 1296
50. J. Ananworanich, R. Nuesch, H.C. Cote, S.J. Kerr, A. Hill, and T. Jupimai Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine - a staccato trial substudy J Antimicrob Chemother 61 2008 1340 1343
51. K.E. Squires, R. Gulick, P. Tebas, J. Santana, V. Mulanovich, and R. Clark A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I) AIDS 14 2000 1591 1600
52. K.J. Smith, R. Buckley, and H. Skelton Lamivudine (3TC)-induced contact dermatitis Cutis 65 2000 227 229
53. Epivir [package insert] 2006 GlaxoSmithKline Research Triangle Park, NC
54. B. Max, and R. Sherer Management of the adverse effects of antiretroviral therapy and medication adherence Clin Infect Dis 30 suppl 2 2000 S96 116
55. Abacavir [package insert] 2008 Glaxo Wellcome Research Trianlge Park, NC
56. R.G. Hewitt Abacavir hypersensitivity reaction Clin Infect Dis 34 2002 1137 1142
57. M. Shapiro, K.M. Ward, and J.J. Stern A near-fatal hypersensitivity reaction to abacavir: case report and literature review AIDS Read 11 2001 222 226
58. R.P. Walensky, J.H. Goldberg, and J.P. Daily Anaphylaxis after rechallenge with abacavir AIDS 13 1999 999 1000
59. L. Escaut, J.Y. Liotier, E. Albengres, N. Cheminot, and D. Vittecoq Abacavir rechallenge has to be avoided in case of hypersensitivity reaction AIDS 13 1999 1419 1420
60. H.M. El-Sahly Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient AIDS 18 2004 359 360
61. P.H. Frissen, J. de Vries, H.M. Weigel, and K. Brinkman Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity AIDS 15 2001 289
62. S. Hetherington, A.R. Hughes, M. Mosteller, D. Shortino, K.L. Baker, and W. Spreen Genetic variations in HLA-B region and hypersensitivity reactions to abacavir Lancet 359 2002 1121 1122
63. S. Mallal, E. Phillips, G. Carosi, J.M. Molina, C. Workman, and J. Tomazic HLA-B5701 screening for hypersensitivity to abacavir N Engl J Med 358 2008 568 579
64. H.Y. Sun, C.C. Hung, P.H. Lin, S.F. Chang, C.Y. Yang, and S.Y. Chang Incidence of abacavir hypersensitivity and its relationship with HLA-B5701 in HIV-infected patients in Taiwan J Antimicrob Chemother 60 2007 599 604
65. A. Rauch, D. Nolan, A. Martin, E. McKinnon, C. Almeida, and S. Mallal Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the western Australian HIV cohort study Clin Infect Dis 43 2006 99 102
66. A.M. Martin, D. Nolan, S. Gaudieri, C.A. Almeida, R. Nolan, and I. James Predisposition to abacavir hypersensitivity conferred by HLA-B5701 and a haplotypic Hsp70-hom variant Proc Natl Acad Sci U S A 101 2004 4180 4185
67. S. Hughes, A. Hughes, C. Brothers, W. Spreen, D. Thorborn CNA106030 Study T PREDICT-1 (CNA106030): The first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events Pharm Stat 7 2008 121 129
68. A.R. Hughes, M. Mosteller, A.T. Bansal, K. Davies, S.A. Haneline, and E.H. Lai Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations Pharmacogenomics 5 2004 203 211
69. Dart Trial T Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: A randomized double-blind trial (NORA) Trop Med Int Health 13 2008 6 16
70. M. Saag, R. Balu, E. Phillips, P. Brachman, C. Martorell, and W. Burman High sensitivity of human leukocyte antigen-b5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients Clin Infect Dis 46 2008 1111 1118
71. D. Zucman, P. Truchis, C. Majerholc, S. Stegman, and S. Caillat-Zucman Prospective screening for human leukocyte antigen-B5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population J Acquir Immune Defic Syndr 45 2007 1 3
72. S.T. Sadiq, and M. Pakianathan Uncertainties of routine HLA B5701 testing in black African HIV cohorts in the UK Sex Transm Infect 83 2007 181 182
73. E.J. Phillips, G.A. Wong, R. Kaul, K. Shahabi, D.A. Nolan, and S.R. Knowles Clinical and immunogenetic correlates of abacavir hypersensitivity AIDS 19 2005 979 981
74. A.L. Panlilio, D.M. Cardo, L.A. Grohskopf, W. Heneine, C.S. Ross US Public Health Service Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis MMWR Recomm Rep 54 RR-9 2005 1 17
75. P. Del Giudice, F. Vandenbos, C. Perrin, E. Bernard, L. Marq, and P. Dellamonica Sweet's syndrome following abacavir therapy J Am Acad Dermatol 51 2004 474 475
76. F.S. Rousseau, C. Wakeford, H. Mommeja-Marin, I. Sanne, C. Moxham, and J. Harris Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients J Infect Dis 188 2003 1652 1658
77. M.S. Saag, P. Cahn, F. Raffi, M. Wolff, D. Pearce, and J.M. Molina Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: A randomized trial JAMA 292 2004 180 189
78. Mondou E, Quinn JB, Shaw A, Hinkle J, Adda N, Rousseau F. Incidence of skin discoloration across phase III clinical trials of emtricitabine (FTC). Presented at the XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004.
79. M. Nelson, and M. Schiavone Emtricitabine (FTC) for the treatment of HIV infection Int J Clin Pract 58 2004 504 510
80. Viread [package insert] 2008 Gilead Sciences Palo Alto, CA
81. Staszewiski S, Gallant J, Pozniak AL, Sulieman JMAH, De Jesus E, Koenig E, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. Presented at the XIVth International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
82. S.M. Lockhart, R.C. Rathbun, J.R. Stephens, D.L. Baker, D.A. Drevets, and R.A. Greenfield Cutaneous reactions with tenofovir disoproxil fumarate: A report of nine cases AIDS 21 2007 1370 1373
83. C. Flexner HIV-protease inhibitors N Engl J Med 338 1998 1281 1292
84. K.A. Lichtenstein, K.M. Delaney, C. Armon, D.J. Ward, A.C. Moorman, and K.C. Wood Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients J Acquir Immune Defic Syndr 32 2003 48 56
85. X. Duval, V. Journot, C. Leport, G. Chene, M. Dupon, and L. Cuzin Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy Clin Infect Dis 39 2004 248 255
86. P. Bonfanti, A. Capetti, P. Riva, L. Testa, and T. Quirino Hypersensitivity reactions during antiretroviral regimens with protease inhibitors AIDS 11 1997 1301 1302
87. L.K. Gajewski, A.J. Grimone, K.M. Melbourne, and G.J. Vanscoy Characterization of rash with indinavir in a national patient cohort Ann Pharmacother 33 1999 17 21
88. F. Bouscarat, M.H. Prevot, and S. Matheron Alopecia associated with indinavir therapy N Engl J Med 341 1999 618
89. F. Bouscarat, C. Bouchard, and D. Bouhour Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir N Engl J Med 338 1998 1776 1777
90. J. Garcia-Silva, M. Almagro, C. Pena-Penabad, and E. Fonseca Indinavir-induced retinoid-like effects: incidence, clinical features and management Drug Saf 25 2002 993 1003
91. D. Calista, and A. Boschini Cutaneous side effects induced by indinavir Eur J Dermatol 10 2000 292 296
92. C.W. James, K.C. McNelis, D.M. Cohen, S. Szabo, and A.K. Bincsik Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy Ann Pharmacother 35 2001 881 884
93. J.M. Lenhard, J.E. Weiel, M.A. Paulik, and E.S. Furfine Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir Biochem Pharmacol 59 2000 1063 1068
94. R. Viraben, and C. Aquilina Indinavir-associated lipodystrophy AIDS 12 1998 F37 F39
95. K.A. Lichtenstein Redefining lipodystrophy syndrome: risks and impact on clinical decision making J Acquir Immune Defic Syndr 39 2005 395 400
96. J.P. Dank, and R. Colven Protease inhibitor-associated angiolipomatosis J Am Acad Dermatol 42 1 pt 1 2000 129 131
97. C.J. Cohen, J. Hellinger, and D. Norris Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection AIDS Read 10 2000 296 299
98. A. Andrade, and C. Flexner HIV-related drug metabolism and cytochrome P450 enzymes AIDS Clin Care 12 2000 91 95
99. R.K. Zeldin, and R.A. Petruschke Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients J Antimicrob Chemother 53 2004 4 9
100. D.W. Cameron, M. Heath-Chiozzi, S. Danner, C. Cohen, S. Kravcik, and C. Maurath Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group Lancet 351 1998 543 549
101. Norvir [package insert] 2008 Abbott Laboratories Abbott Park, IL
102. D.W. Cameron, A.J. Japour, Y. Xu, A. Hsu, J. Mellors, and C. Farthing Ritonavir and saquinavir combination therapy for the treatment of HIV infection AIDS 13 1999 213 224
103. K.J. Smith, J. Yeager, and H. Skelton Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor Cutis 66 2000 29 32
104. Viracept [package insert] 2007 Agouron Pharmaceuticals San Diego, CA
105. P. Demoly, D. Messaad, A. Trylesinski, V. Faucherre, J. Fabre, and J. Reynes Nelfinavir-induced urticaria and successful desensitization J Allergy Clin Immunol 102 1998 875 876
106. C. Fortuny, M.A. Vicente, M.M. Medina, and A. Gonzalez-Ensenat Rash as side-effect of nelfinavir in children AIDS 14 2000 335 336
107. D. Calista Maculo-papular rash induced by lopinavir/ritonavir Eur J Dermatol 15 2005 97 98
108. R. Manfredi, and S. Sabbatani Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function AIDS 20 2006 2399 2400
109. J.C. Goodgame, J.C. Pottage Jr., H. Jablonowski, W.D. Hardy, A. Stein, and M. Fischl Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team Antivir Ther 5 2000 215 225
110. J.C. Gathe Jr., R. Wood, I. Sanne, E. DeJesus, D. Schurmann, and A. Gladysz Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study Clin Ther 28 2006 745 754
111. A. Rodriguez-French, J. Boghossian, G.E. Gray, J.P. Nadler, A.R. Quinones, and G.E. Sepulveda The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients J Acquir Immune Defic Syndr 35 2004 22 32
112. Lexiva [package insert] 2008 GlaxoSmithKline Research Trianlge Park, NC
113. K. Squires, A. Lazzarin, J.M. Gatell, W.G. Powderly, V. Pokrovskiy, and J.F. Delfraissy Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV J Acquir Immune Defic Syndr 36 2004 1011 1019
114. R.L. Murphy, I. Sanne, P. Cahn, P. Phanuphak, L. Percival, and T. Kelleher Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results AIDS 17 2003 2603 2614
115. Reyataz [package insert] 2008 Bristol-Meyers Squibb Company New York
116. J.S. Orman, and C.M. Perry Tipranavir: A review of its use in the management of HIV infection Drugs 68 2008 1435 1463
117. Aptivus [package insert] 2008 Boehringer Ingelheim Pharmaceuticals Ingelheim, Germany
118. K.H. Busse, and S.R. Penzak Darunavir: A second-generation protease inhibitor Am J Health Syst Pharm 64 2007 1593 1602
119. J.V. Madruga, D. Berger, M. McMurchie, F. Suter, D. Banhegyi, and K. Ruxrungtham Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial Lancet 370 2007 49 58
120. J.M. Molina, C. Cohen, C. Katlama, B. Grinsztejn, A. Timerman, and J. Pedro Rde Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3 J Acquir Immune Defic Syndr 46 2007 24 31 (Pubitemid 47514614)
121. Prezista [package insert] 2006 Tibotec Therapeutics Titusville, NJ